| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10138241 | Journal of Affective Disorders | 2019 | 68 Pages |
Abstract
A consistent trend was observed such that medical costs increased and patient HRQoL and health status decreased by increasing level of TRD/non-response within an MDD episode. These findings highlight the need for improved therapies for TRD to help reduce disease burden.
Keywords
VASHUIPICOSSF-12MGHMDEQALYSF-36HRQOLSF-6DSNRIEQ-5DTRDHAM-DOECDMDDECTPRISMAYLDSTAR*DPreferred Reporting Items for Systematic Reviews and Meta-AnalysesMajor depressive disorderDepressive disorder, majorTreatment-resistant depressionstandard deviationsUnited States of AmericaUnited StatesUSABurdenMassachusetts General HospitalSequenced Treatment Alternatives to Relieve DepressionElectroconvulsive therapyCognitive behavioral therapyCognitive therapyCBTOrganization for Economic Cooperation and DevelopmentQuality-adjusted life yearsHealth Utilities IndexAntidepressantMajor depressive episodeReviewMeshvisual analogue scaleHamilton Depression Rating ScaleSelective serotonin reuptake inhibitorserotonin norepinephrine reuptake inhibitorSSRIMedical Subject HeadingsUnited KingdomHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
Karissa M. Johnston, Lauren C. Powell, Ian M. Anderson, Shelagh Szabo, Stephanie Cline,